ABC | Volume 113, Nº3, Setembro 2019

Atualização Atualização da Diretriz de Ressuscitação Cardiopulmonar e Cuidados Cardiovasculares de Emergência da Sociedade Brasileira de Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(3):449-663 521. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;;2(8498):57-66. 522. International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med. 1984;310(1):9-15. 523. Al-Reesi A, Al-Zadjali N, Perry J, Fergusson D, Al-Shamsi M, Al-Thagafi M, et al. Do beta-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and meta-analysis. CJEM. 2008;10(3):215-23. 524. Horiuchi Y, Tanimoto S, Aoki J, Nakajima H, Hara K, Tanabe K. Effects of beta-blockers on left ventricular remodeling in patients with preserved ejection fraction after acutemyocardial infarction. Int J Cardiol. 2016Oct 15;221:765-9. 525. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(17):1814-21. 526. Teshima Y, Yufu K, Akioka H, Iwao T, Anan F, Nakagawa M, et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol. 2009;53(1):58-64. 527. Lenderink T, Boersma E, Gitt AK, Zeymer U, Wallentin L, Van de Werf F, et al. Patients using statin treatment within 24 h after admission for ST- elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J. 2006;27(15):1799-804. 528. Spencer FA, FonarowGC, Frederick PD, Wright RS, Every N, Goldberg RJ, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevationmyocardial infarction: national registry of myocardial infarction. Arch Intern Med. 2004;164(19):2162-8. 529. Heeschen C, Hamm CW, Laufs U, Snapinn S, BohmM, White HD, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105(12):1446-52. 530. Pourafkari L, Visnjevac O, Ghaffari S, Nader ND. Statin drugs mitigate cellular inflammatory response after ST elevation myocardial infarction, but do not affect in-hospital mortality. J Cardiovasc Thorac Res. 2016;8(1):34-9. 531. Marenzi G, Cosentino N, Cortinovis S, Milazzo V, Rubino M, Cabiati A, et al. Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Am J Cardiol. 2015;116(12):1791-7. 532. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25(20):1822-8. 533. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49(12):1272-8. 534. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. 535. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366(1):54-63. 536. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acutemyocardial infarction: collaborative overviewofearlymortalityandmajormorbidityresultsfromallrandomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-22. 537. Gruppo Italiano per lo Studio della Streptochinasi nell'InfartoMiocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1(8478):397-402. 538. SIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339(8796):753-70. 539. GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673-82. 540. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, VanDeWerf F, Adgey J, ArdissinoD, Armstrong PW, Aylward P, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-22. 541. Avezum Jr A, Feldman A, Carvalho AC, Sousa AC, Mansur Ade P, Bozza AE, et al. V Guideline of the Brazilian Society of Cardiology on Acute Myocardial Infarction Treatment with ST Segment Elevation. Arq Bras Cardiol. 2015;105(2 Suppl 1):1-105. 542. Pastore CA, Pinho JA, Pinho C, Samesima N, Pereira Filho HG, Kruse J, et al. III Diretrizes da Sociedade Brasileira de Cardiologia sobre analise e emissao de laudos eletrocardiograficos. Arq Bras Cardiol. 2016;106(4 Suppl 1):1-23. 543. Squire IB, Lawley W, Fletcher S, Holme E, Hillis WS, Hewitt C, et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acutemyocardial infarction. Eur Heart J. 1999;20(17):1245-52. 544. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329(22):1615-22. 545. Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, et al. Extended mortality benefit of early postinfarction reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation. 1998;97(16):1549-56. 546. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348(9030):771-5. 547. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparisonofprimarycoronaryangioplastyand intravenousthrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278(23):2093-8. 548. Grines CL, Browne KF, Marco J, RothbaumD, StoneGW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993;328(10):673-9. 549. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J. 2003;24(1):94-104. 550. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349(8):733-42. 551. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty inMyocardial Infarction Study Group. N Engl J Med. 1999;341(26):1949-56. 552. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346(13):957-66. 553. Palmerini T, Biondi-Zoccai G, Della RivaD, Mariani A, SabateM, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence 640